董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Barry J. Simon | 男 | Independent Director | 60 | 42.03万美元 | 316.76 | 2025-12-12 |
| Michael Blaszyk | 男 | Independent Director | 73 | 51.34万美元 | 79.55 | 2025-12-12 |
| Linda Maxwell | 女 | Independent Director | 51 | 48.92万美元 | 45.18 | 2025-12-12 |
| Wesley Clark | 男 | Independent Director | 80 | 47.06万美元 | 45.98 | 2025-12-12 |
| Richard Adcock | 男 | Chief Executive Officer,President and Director | 56 | 1271.70万美元 | 400.88 | 2025-12-12 |
| Christobel Selecky | 女 | Independent Director | 70 | 47.73万美元 | 35.18 | 2025-12-12 |
| Patrick Soon Shiong | 男 | Executive Chairman of the Board and Global Chief Scientific and Medical Officer | 73 | 1229.33万美元 | 74551.83 | 2025-12-12 |
| Bruce Wendel | 男 | Independent Director | 72 | 30.27万美元 | 未持股 | 2025-12-12 |
| Cheryl L. Cohen | 女 | Lead Independent Director | 59 | 51.42万美元 | 73.05 | 2025-12-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Adcock | 男 | Chief Executive Officer,President and Director | 56 | 1271.70万美元 | 400.88 | 2025-12-12 |
| David Sachs | 男 | Chief Financial Officer | 47 | 424.45万美元 | 111.43 | 2025-12-12 |
| Patrick Soon Shiong | 男 | Executive Chairman of the Board and Global Chief Scientific and Medical Officer | 73 | 1229.33万美元 | 74551.83 | 2025-12-12 |
董事简历
中英对照 | 中文 | 英文- Barry J. Simon
-
Barry J. Simon，2015年3月起，担任本公司的总裁、首席运营官、董事。2007年至2015年3月，他担任本公司的总裁、首席执行官、董事。加入本公司之前，他在多个公司担任过各种高管及咨询职务，包括：Roche Labs, F. Hoffmann-La Roche， 全球性的医疗保健公司；Connetics Corp.， 专业药品公司；Immunomedics, Inc.， 生物药品公司；Immusol, Inc.， 生物药品公司；HealthPro BioVentures, LLC， 医疗保健与生命科学投资银行；NorthSound Capital, LLC， 对冲基金。他曾就读于London School of Business、the Amos Tuck School of Business at Dartmouth College的企业培训课程；曾受过感染性疾病、麻醉、内科的临床训练，在纽约的SUNY Downstate, Health Sciences Center 获得医学博士学位。
Barry J. Simon,has served as a member of the Board since 2007 and as Chief Corporate Affairs Officer of the company since March 2021. He previously served as Immunitybio, Inc. President and Chief Administrative Officer from January 2017 to March 2021, and as President and Chief Operating Officer from 2015 to 2016. From 2007 to 2015, he was Immunitybio, Inc. President and Chief Executive Officer. He has served as president, chief executive officer and chairman of Brink Biologics Inc., a bioanalytics, reagents and testing services company (a company affiliated with Dr. Soon-Shiong), since March 2015. Previously, he held vice president, senior level, and advisory positions at F. Hoffmann-La Roche, a global healthcare company, Roche Labs, a pharmaceuticals company, Connetics Corporation, a specialty pharmaceutical company, Immunomedics, a biopharmaceutical company, Immusol, a biopharmaceutical company, HealthPro BioVentures, LLC, a healthcare and life sciences investment bank, and NorthSound Capital, LLC, a U.S.-based hedge fund. He previously served as a director of Viracta Therapeutics, Inc., a biopharmaceutical company, from July 2017 to November 2020 and March 2021 to December 2024, and as a director of Cue Biopharma, Inc. (Nasdaq:CUE), a biopharmaceutical company, from 2016 to June 2021. He has broad experience in public and private settings, having led private and public equity offerings, product and portfolio divestitures and acquisitions, strategic licensing and joint ventures, as well as commercial product launches, investigational new drug (IND) and biologics license application (BLA) regulatory filings, human-enabling programs, manufacturing, quality control and life cycle management. He has worked across several therapeutic areas including oncology, virology, ophthalmology and dermatology on products launches including Xeloda, Pegasys, Fortovase, Tamiflu, Camptobell, Boniva, Fuzeon, Valcyt, and Accutane. He attended corporate training programs through the London School of Business and Amos Tuck School of Business at Dartmouth College. Dr. Simon trained clinically in Infectious Diseases at Albert Einstein College of Medicine, Anesthesiology at The Mount Sinai Medical Center, and Internal Medicine at New York University and received his M.D. from the SUNY Downstate Health Sciences Center in New York. - Barry J. Simon，2015年3月起，担任本公司的总裁、首席运营官、董事。2007年至2015年3月，他担任本公司的总裁、首席执行官、董事。加入本公司之前，他在多个公司担任过各种高管及咨询职务，包括：Roche Labs, F. Hoffmann-La Roche， 全球性的医疗保健公司；Connetics Corp.， 专业药品公司；Immunomedics, Inc.， 生物药品公司；Immusol, Inc.， 生物药品公司；HealthPro BioVentures, LLC， 医疗保健与生命科学投资银行；NorthSound Capital, LLC， 对冲基金。他曾就读于London School of Business、the Amos Tuck School of Business at Dartmouth College的企业培训课程；曾受过感染性疾病、麻醉、内科的临床训练，在纽约的SUNY Downstate, Health Sciences Center 获得医学博士学位。
- Barry J. Simon,has served as a member of the Board since 2007 and as Chief Corporate Affairs Officer of the company since March 2021. He previously served as Immunitybio, Inc. President and Chief Administrative Officer from January 2017 to March 2021, and as President and Chief Operating Officer from 2015 to 2016. From 2007 to 2015, he was Immunitybio, Inc. President and Chief Executive Officer. He has served as president, chief executive officer and chairman of Brink Biologics Inc., a bioanalytics, reagents and testing services company (a company affiliated with Dr. Soon-Shiong), since March 2015. Previously, he held vice president, senior level, and advisory positions at F. Hoffmann-La Roche, a global healthcare company, Roche Labs, a pharmaceuticals company, Connetics Corporation, a specialty pharmaceutical company, Immunomedics, a biopharmaceutical company, Immusol, a biopharmaceutical company, HealthPro BioVentures, LLC, a healthcare and life sciences investment bank, and NorthSound Capital, LLC, a U.S.-based hedge fund. He previously served as a director of Viracta Therapeutics, Inc., a biopharmaceutical company, from July 2017 to November 2020 and March 2021 to December 2024, and as a director of Cue Biopharma, Inc. (Nasdaq:CUE), a biopharmaceutical company, from 2016 to June 2021. He has broad experience in public and private settings, having led private and public equity offerings, product and portfolio divestitures and acquisitions, strategic licensing and joint ventures, as well as commercial product launches, investigational new drug (IND) and biologics license application (BLA) regulatory filings, human-enabling programs, manufacturing, quality control and life cycle management. He has worked across several therapeutic areas including oncology, virology, ophthalmology and dermatology on products launches including Xeloda, Pegasys, Fortovase, Tamiflu, Camptobell, Boniva, Fuzeon, Valcyt, and Accutane. He attended corporate training programs through the London School of Business and Amos Tuck School of Business at Dartmouth College. Dr. Simon trained clinically in Infectious Diseases at Albert Einstein College of Medicine, Anesthesiology at The Mount Sinai Medical Center, and Internal Medicine at New York University and received his M.D. from the SUNY Downstate Health Sciences Center in New York.
- Michael Blaszyk
-
Michael Blaszyk，2015年7月以来，他曾一直担任董事会的成员。他曾一直担任Dignity Health公司（原为Catholic Healthcare West公司，非营利性公益公司）的首席财务官（2000年12月以来）。加入Dignity Health公司之前，他曾担任俄亥俄州克利夫兰大学医院的卫生系统（University Hospitals Health System，一个卫生保健系统）的高级副总裁兼首席财务官（从1997年10月到2000年12月）。他此前也曾担任Mercer公司（原为William M. Mercer公司，全球咨询公司）的东北地区卫生保健供应商咨询实践的管理合伙人，以及全球咨询公司（一个非盈利的学术医疗中心）的执行副总裁。他是Sound Physicians公司（一家费森尤斯公司）的董事和审计委员会成员。他持有Wayne State University的生命科学学士学位，以及科罗拉多大学（University of Colorado）的卫生服务管理硕士学位。
Michael Blaszyk has served as a member of board of directors since July 2015. Mr. Blaszyk has served as the chief financial officer for Dignity Health formerly known as Catholic Healthcare West, a not-for-profit public benefit corporation, since December 2000. Prior to joining Dignity Health, Mr. Blaszyk was the senior vice president and chief financial officer for University Hospitals Health System in Cleveland, Ohio, a healthcare system, from October 1997 to December 2000. Mr. Blaszyk also previously served as the managing partner of the Northeast region Health Care Provider Consulting Practice for Merger LLC (formerly known as William M. Mercer), a global consulting firm, and the executive vice president at Boston Medical Center, a non-profit academic medical center. Mr. Blaszyk is a director and member of the audit committee of Sound Physicians, Inc., a Fresenius company. He received his bachelor's degree in life sciences from Wayne State University and his master's degree in health services administration from the University of Colorado. - Michael Blaszyk，2015年7月以来，他曾一直担任董事会的成员。他曾一直担任Dignity Health公司（原为Catholic Healthcare West公司，非营利性公益公司）的首席财务官（2000年12月以来）。加入Dignity Health公司之前，他曾担任俄亥俄州克利夫兰大学医院的卫生系统（University Hospitals Health System，一个卫生保健系统）的高级副总裁兼首席财务官（从1997年10月到2000年12月）。他此前也曾担任Mercer公司（原为William M. Mercer公司，全球咨询公司）的东北地区卫生保健供应商咨询实践的管理合伙人，以及全球咨询公司（一个非盈利的学术医疗中心）的执行副总裁。他是Sound Physicians公司（一家费森尤斯公司）的董事和审计委员会成员。他持有Wayne State University的生命科学学士学位，以及科罗拉多大学（University of Colorado）的卫生服务管理硕士学位。
- Michael Blaszyk has served as a member of board of directors since July 2015. Mr. Blaszyk has served as the chief financial officer for Dignity Health formerly known as Catholic Healthcare West, a not-for-profit public benefit corporation, since December 2000. Prior to joining Dignity Health, Mr. Blaszyk was the senior vice president and chief financial officer for University Hospitals Health System in Cleveland, Ohio, a healthcare system, from October 1997 to December 2000. Mr. Blaszyk also previously served as the managing partner of the Northeast region Health Care Provider Consulting Practice for Merger LLC (formerly known as William M. Mercer), a global consulting firm, and the executive vice president at Boston Medical Center, a non-profit academic medical center. Mr. Blaszyk is a director and member of the audit committee of Sound Physicians, Inc., a Fresenius company. He received his bachelor's degree in life sciences from Wayne State University and his master's degree in health services administration from the University of Colorado.
- Linda Maxwell
-
Linda Maxwell,2005年起担任外科医生；2015年6月起担任生物医学区域瑞尔森大学执行董事；牛津大学技术转让经理（2013年6月至2014年7月）。
Linda Maxwell,Surgeon since 2005; Executive Director of Biomedical Zone Ryerson University since June 2015; Technology Transfer Manager at University of Oxford (June 2013 to July 2014). - Linda Maxwell,2005年起担任外科医生；2015年6月起担任生物医学区域瑞尔森大学执行董事；牛津大学技术转让经理（2013年6月至2014年7月）。
- Linda Maxwell,Surgeon since 2005; Executive Director of Biomedical Zone Ryerson University since June 2015; Technology Transfer Manager at University of Oxford (June 2013 to July 2014).
- Wesley Clark
-
Wesley Clark，自2021年3月起担任ImmunityBio公司董事会成员。他于2021年2月至2021年3月9日期间担任ImmunityBio，Inc.（一家私营公司）的董事会成员。他在美国陆军服役了34年，在1996年通过晋升获得了他作为正式将领的第四颗星。他曾于1997年至2000年担任北约欧洲最高盟军指挥官，在科索沃战争中指挥盟军行动。克拉克将军在其整个职业生涯中都获得了极高的勋章，他被美国总统William J. Clinton授予美国总统自由勋章。自2003年起，他担任Wesley K. Clark & Associates，LLC的董事长兼首席执行官，该公司是一家专注于业务发展、危机支持和战略传播的战略咨询公司。自2010年起，他担任精品投资银行Enverra，Inc.的董事长兼首席执行官。他目前自2022年8月起担任Directa Plus S.P.A.董事会成员，自2022年12月起担任MCF Energy Ltd.董事会成员。Gen. Clark此前曾于2020年至2023年在Equinox Gold Corp.以及2010年至2018年在Rentech，Inc.的董事会任职。他毕业于美国西点军校，在那里他是班级告别演说者。从西点军校毕业后，他获得了牛津大学的罗德奖学金，在那里他获得了哲学、政治和经济学学位。曾获指挥总参高等专科学校军事学硕士学位。
Wesley Clark a director since June 12, 2025, has served as a member of the Board of Directors of ImmunityBio, Inc. (NASDAQ: IBRX) since March 2021. Since 2003, he has served as chairman and chief executive officer of sley K. Clark & Associates, LLC, a strategic consulting firm specializing in biness development, crisis support and strategic communications. Since 2010, he has served as chairman and chief executive officer of Enverra, Inc., a boutique investment bank. General Clark has been a director of special purpose companies from December 14, 2021 to December 13, 2024, General Clark served as a director of Swiftmerge Acquisition Corp., and from September 2005 to October 2009, General Clark was a director of Argyle Security, Inc., formerly Argyle Security Acquisition Corporation. See "Prior SPAC Experience." He served for 34 years in the U.S. Army, rising through the ranks to earn his fth star as a full general in 1996. He served as the Supreme Allied Commander Europe of NATO from 1997 to 2000, where he commanded Operation Allied Force in the Kosovo War. Highly decorated throughout his career, Gen. Clark was awarded the U.S. Presidential Medal of Freedom by President William J. Clinton. He has been a director of Directa Pl S.p.A. since Augt 2022 and MCF Energy Ltd. since December 2022. Gen. Clark previoly served on the boards of directors of Equinox Gold Corp. from 2020 to 2023, and Rentech, Inc. from 2010 to 2018. He is a graduate of the U.S. Military Academy at st Point, where he was class valedictorian. After graduating from st Point, he was awarded a Rhodes Scholarship to the University of Oxford where he earned degrees in philosophy, politics and economics. He earned a master's degree in military science from the Command and General Staff College. - Wesley Clark，自2021年3月起担任ImmunityBio公司董事会成员。他于2021年2月至2021年3月9日期间担任ImmunityBio，Inc.（一家私营公司）的董事会成员。他在美国陆军服役了34年，在1996年通过晋升获得了他作为正式将领的第四颗星。他曾于1997年至2000年担任北约欧洲最高盟军指挥官，在科索沃战争中指挥盟军行动。克拉克将军在其整个职业生涯中都获得了极高的勋章，他被美国总统William J. Clinton授予美国总统自由勋章。自2003年起，他担任Wesley K. Clark & Associates，LLC的董事长兼首席执行官，该公司是一家专注于业务发展、危机支持和战略传播的战略咨询公司。自2010年起，他担任精品投资银行Enverra，Inc.的董事长兼首席执行官。他目前自2022年8月起担任Directa Plus S.P.A.董事会成员，自2022年12月起担任MCF Energy Ltd.董事会成员。Gen. Clark此前曾于2020年至2023年在Equinox Gold Corp.以及2010年至2018年在Rentech，Inc.的董事会任职。他毕业于美国西点军校，在那里他是班级告别演说者。从西点军校毕业后，他获得了牛津大学的罗德奖学金，在那里他获得了哲学、政治和经济学学位。曾获指挥总参高等专科学校军事学硕士学位。
- Wesley Clark a director since June 12, 2025, has served as a member of the Board of Directors of ImmunityBio, Inc. (NASDAQ: IBRX) since March 2021. Since 2003, he has served as chairman and chief executive officer of sley K. Clark & Associates, LLC, a strategic consulting firm specializing in biness development, crisis support and strategic communications. Since 2010, he has served as chairman and chief executive officer of Enverra, Inc., a boutique investment bank. General Clark has been a director of special purpose companies from December 14, 2021 to December 13, 2024, General Clark served as a director of Swiftmerge Acquisition Corp., and from September 2005 to October 2009, General Clark was a director of Argyle Security, Inc., formerly Argyle Security Acquisition Corporation. See "Prior SPAC Experience." He served for 34 years in the U.S. Army, rising through the ranks to earn his fth star as a full general in 1996. He served as the Supreme Allied Commander Europe of NATO from 1997 to 2000, where he commanded Operation Allied Force in the Kosovo War. Highly decorated throughout his career, Gen. Clark was awarded the U.S. Presidential Medal of Freedom by President William J. Clinton. He has been a director of Directa Pl S.p.A. since Augt 2022 and MCF Energy Ltd. since December 2022. Gen. Clark previoly served on the boards of directors of Equinox Gold Corp. from 2020 to 2023, and Rentech, Inc. from 2010 to 2018. He is a graduate of the U.S. Military Academy at st Point, where he was class valedictorian. After graduating from st Point, he was awarded a Rhodes Scholarship to the University of Oxford where he earned degrees in philosophy, politics and economics. He earned a master's degree in military science from the Command and General Staff College.
- Richard Adcock
-
Richard Adcock，自2020年10月起担任首席执行官，自2021年3月起担任公司总裁和董事会成员。他在医疗保健行业拥有超过30年的领导经验。2018年1月至2020年9月，他担任加利福尼亚州Verity Health System，Inc.（Verity Health）的首席执行官，这是一家非营利性公益公司医疗保健提供商，他通过一次成功的重组事件指导了该公司。在加入Verity Health之前，他曾在Sanford Health（一家非营利性综合医疗保健交付系统）担任过各种职务，包括在2004年至2017年期间担任其首席创新官、总裁、执行副总裁和董事。在加入Sanford Health之前，他曾在GE Healthcare担任全球工程总监。Adcock先生拥有北方州立大学工商管理学士学位和凤凰城大学医疗保健管理硕士学位。
Richard Adcock,has served as Chief Executive Officer since October 2020 and as President of the company and a member of the Board since March 2021.He has over 30 years of leadership experience in the healthcare industry. From January 2018 to September 2020, he served as chief executive officer of Verity Health System of California, Inc. (Verity Health), a nonprofit public benefit corporation healthcare provider, that he steered through a successful restructuring event. Prior to joining Verity Health, he served in various capacities at Sanford Health, a not-for-profit integrated healthcare delivery system, including as its chief innovation officer, president, executive vice president and director from 2004 to 2017. Prior to Sanford Health, he served as global engineering director at GE Healthcare. Mr. Adcock holds a B.S. in Business Administration from Northern State University and an M.B.A. in Healthcare Management from University of Phoenix. - Richard Adcock，自2020年10月起担任首席执行官，自2021年3月起担任公司总裁和董事会成员。他在医疗保健行业拥有超过30年的领导经验。2018年1月至2020年9月，他担任加利福尼亚州Verity Health System，Inc.（Verity Health）的首席执行官，这是一家非营利性公益公司医疗保健提供商，他通过一次成功的重组事件指导了该公司。在加入Verity Health之前，他曾在Sanford Health（一家非营利性综合医疗保健交付系统）担任过各种职务，包括在2004年至2017年期间担任其首席创新官、总裁、执行副总裁和董事。在加入Sanford Health之前，他曾在GE Healthcare担任全球工程总监。Adcock先生拥有北方州立大学工商管理学士学位和凤凰城大学医疗保健管理硕士学位。
- Richard Adcock,has served as Chief Executive Officer since October 2020 and as President of the company and a member of the Board since March 2021.He has over 30 years of leadership experience in the healthcare industry. From January 2018 to September 2020, he served as chief executive officer of Verity Health System of California, Inc. (Verity Health), a nonprofit public benefit corporation healthcare provider, that he steered through a successful restructuring event. Prior to joining Verity Health, he served in various capacities at Sanford Health, a not-for-profit integrated healthcare delivery system, including as its chief innovation officer, president, executive vice president and director from 2004 to 2017. Prior to Sanford Health, he served as global engineering director at GE Healthcare. Mr. Adcock holds a B.S. in Business Administration from Northern State University and an M.B.A. in Healthcare Management from University of Phoenix.
- Christobel Selecky
-
Christobel Selecky，自2021年3月起担任董事会成员。她于2020年8月至2021年3月9日期间担任ImmunityBio，Inc.（一家私营公司）的董事会成员。Selecky女士拥有超过35年的医疗保健行业经验。她是旗下医疗保健咨询公司Population Health Strategies的负责人，自2009年以来，她一直为管理团队、公司和投资者提供战略咨询，帮助提高患者参与度、人口健康结果以及医疗保健成本管理。自2014年起，她担任私营医疗技术公司Ceresti Health的战略顾问，并自2017年起担任加州大学欧文分校MBA项目的医疗保健创业讲师。在FHP国际公司14年的职业生涯中，她担任过多个领导职务，该公司于1995年结束，包括担任FHP加州健康计划总裁。随后，她与人共同创立，并担任疾病和人口健康管理领域的全国领先企业LifeMasters Supported SelfCare的总裁、首席执行官、执行董事长。她目前担任TelePerformance SE（TEP – ISIN：FR0000051807 – Reuters：TEPRF.PA – Bloomberg：TEP FP）（一家提供商业服务的上市公司）、Satellite Healthcare（一家领先的肾透析和相关服务的非营利提供商）和Griswold Home Care（一家私营的非医疗家庭护理公司）的董事会成员。她活跃于NACD（她是太平洋西南分会的董事会成员）、私人董事协会和女性公司董事等多个董事会治理组织，并一直是她所服务的董事会审计、薪酬、治理和其他委员会的成员。Selecky女士获得了特拉华大学的学士学位和雪城大学的硕士学位。
Christobel Selecky,has served as a member of the Board since March 2021. She served on the board of directors of ImmunityBio, Inc. (a private company) from August 2020 until March 9, 2021. Ms. Selecky has more than 35 years of healthcare industry experience. She is the principal at Population Health Strategies, her healthcare consultancy, where since 2009 she has provided strategic consulting to management teams, companies and investors, helping improve patient engagement, population health outcomes, and healthcare cost management. Since 2014 she has served as a Strategic Advisor at Ceresti Health, a privately-held healthcare technology company, and has served as a lecturer in Healthcare Entrepreneurship for the M.B.A. program at the University of California, Irvine since 2017. She held several leadership positions over her 14-year career at FHP International Corporation, which ended in 1995 including as President of the FHP California Health Plan. She subsequently co-founded, and served as President, CEO, and Executive Chairman of LifeMasters Supported SelfCare, a national leader in the field of disease and population health management. She currently serves on the boards of directors of Teleperformance SE (TEP – ISIN: FR0000051807 – Reuters: TEPRF.PA – Bloomberg: TEP FP), a public company providing business services, Satellite Healthcare, a leading not-for-profit provider of kidney dialysis and related services, and Griswold Home Care, a privately-held non-medical home care company. She is active in several board governance organizations such as NACD (where she is a board member of the Pacific Southwest Chapter), the Private Directors Association, and Women Corporate Directors and has been a member of audit, compensation, governance and other committees of boards of directors on which she has served. Ms. Selecky received her B.A. from the University of Delaware and her M.A. from Syracuse University. - Christobel Selecky，自2021年3月起担任董事会成员。她于2020年8月至2021年3月9日期间担任ImmunityBio，Inc.（一家私营公司）的董事会成员。Selecky女士拥有超过35年的医疗保健行业经验。她是旗下医疗保健咨询公司Population Health Strategies的负责人，自2009年以来，她一直为管理团队、公司和投资者提供战略咨询，帮助提高患者参与度、人口健康结果以及医疗保健成本管理。自2014年起，她担任私营医疗技术公司Ceresti Health的战略顾问，并自2017年起担任加州大学欧文分校MBA项目的医疗保健创业讲师。在FHP国际公司14年的职业生涯中，她担任过多个领导职务，该公司于1995年结束，包括担任FHP加州健康计划总裁。随后，她与人共同创立，并担任疾病和人口健康管理领域的全国领先企业LifeMasters Supported SelfCare的总裁、首席执行官、执行董事长。她目前担任TelePerformance SE（TEP – ISIN：FR0000051807 – Reuters：TEPRF.PA – Bloomberg：TEP FP）（一家提供商业服务的上市公司）、Satellite Healthcare（一家领先的肾透析和相关服务的非营利提供商）和Griswold Home Care（一家私营的非医疗家庭护理公司）的董事会成员。她活跃于NACD（她是太平洋西南分会的董事会成员）、私人董事协会和女性公司董事等多个董事会治理组织，并一直是她所服务的董事会审计、薪酬、治理和其他委员会的成员。Selecky女士获得了特拉华大学的学士学位和雪城大学的硕士学位。
- Christobel Selecky,has served as a member of the Board since March 2021. She served on the board of directors of ImmunityBio, Inc. (a private company) from August 2020 until March 9, 2021. Ms. Selecky has more than 35 years of healthcare industry experience. She is the principal at Population Health Strategies, her healthcare consultancy, where since 2009 she has provided strategic consulting to management teams, companies and investors, helping improve patient engagement, population health outcomes, and healthcare cost management. Since 2014 she has served as a Strategic Advisor at Ceresti Health, a privately-held healthcare technology company, and has served as a lecturer in Healthcare Entrepreneurship for the M.B.A. program at the University of California, Irvine since 2017. She held several leadership positions over her 14-year career at FHP International Corporation, which ended in 1995 including as President of the FHP California Health Plan. She subsequently co-founded, and served as President, CEO, and Executive Chairman of LifeMasters Supported SelfCare, a national leader in the field of disease and population health management. She currently serves on the boards of directors of Teleperformance SE (TEP – ISIN: FR0000051807 – Reuters: TEPRF.PA – Bloomberg: TEP FP), a public company providing business services, Satellite Healthcare, a leading not-for-profit provider of kidney dialysis and related services, and Griswold Home Care, a privately-held non-medical home care company. She is active in several board governance organizations such as NACD (where she is a board member of the Pacific Southwest Chapter), the Private Directors Association, and Women Corporate Directors and has been a member of audit, compensation, governance and other committees of boards of directors on which she has served. Ms. Selecky received her B.A. from the University of Delaware and her M.A. from Syracuse University.
- Patrick Soon Shiong
-
Patrick Soon Shiong，是ImmunityBio公司的创始人，他于2020年10月被任命为董事会执行主席，并于2021年8月11日被任命为公司全球首席科学和医疗官。此前，他于2015年3月至2020年10月担任董事会主席兼首席执行官，于2014年12月至2015年3月担任董事会联席主席，并于2015年1月至2015年3月担任ImmunityBio, Inc.首席医疗官。2011年，他创立了NantWorks，LLC（NantWorks），这是一个由公司组成的生态系统，旨在创建一个变革性的全球健康信息和下一代药物开发网络，用于基因和医学信息的安全共享。Soon-Shiong博士发明并开发了Abraxane，全国首个食品药品监督管理局（FDA）批准的蛋白质纳米颗粒白蛋白结合递送技术，用于治疗癌症。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon-Shiong博士曾担任两家全球制药公司American Pharmaceutical Partners（2008年以46亿美元出售给Fresenius SE）和Abraxis BioScience（2010年以38亿美元出售给新基医药公司）的创始人、董事长和首席执行官。2018年，他成为《洛杉矶时报》、《洛杉矶时报》和《加州时报》旗下其他出版物的所有者和执行董事长。Soon-Shiong博士是Chan Soon-Shiong家族基金会和非营利性医学研究组织Chan Soon-Shiong分子医学研究所的主席。他还担任Access to Advanced Health研究所的董事会主席，该研究所是一家位于西雅图的非营利性生物技术研究机构，专注于与世界上一些最致命的疾病作斗争，包括新冠肺炎、癌症、真菌和寄生虫感染以及其他非传染性疾病。他是伦敦帝国理工学院的客座教授。Soon-Shiong博士拥有威特沃特斯兰德大学的医学学位和不列颠哥伦比亚大学的科学硕士学位。
Patrick Soon Shiong,is the Founder of ImmunityBio, Inc. He was appointed Executive Chairman of the Board in October 2020 and Global Chief Scientific and Medical Officer of the company on August 11, 2021. Previously, he served as the Chairman of the Board and Chief Executive Officer from March 2015 to October 2020, as the Co-Chairman of the Board from December 2014 to March 2015, and as Immunitybio, Inc. Chief Medical Officer from January 2015 to March 2015. In 2011, he founded NantWorks, LLC (NantWorks), an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon-Shiong invented and developed Abraxane, the nation's first Food and Drug Administration (FDA)-approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010, Dr. Soon-Shiong served as founder, chairman, and chief executive officer of two global pharmaceutical companies, American Pharmaceutical Partners (sold to Fresenius SE for $4.6 billion in 2008) and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). In 2018, he became the owner and executive chairman of the Los Angeles Times, Los Angeles Times en Espaol and other publications under the California Times. Dr. Soon-Shiong is chairman of the Chan Soon-Shiong Family Foundation and the Chan Soon-Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He also serves as chair of the board of directors of the Access to Advanced Health Institute, a nonprofit biotech research institute located in Seattle focused on combating some of the world's deadliest diseases, including COVID-19, cancer, fungal and parasitic infections, and other non-communicable diseases. He is a visiting Professor at the Imperial College of London. Dr. Soon-Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia. - Patrick Soon Shiong，是ImmunityBio公司的创始人，他于2020年10月被任命为董事会执行主席，并于2021年8月11日被任命为公司全球首席科学和医疗官。此前，他于2015年3月至2020年10月担任董事会主席兼首席执行官，于2014年12月至2015年3月担任董事会联席主席，并于2015年1月至2015年3月担任ImmunityBio, Inc.首席医疗官。2011年，他创立了NantWorks，LLC（NantWorks），这是一个由公司组成的生态系统，旨在创建一个变革性的全球健康信息和下一代药物开发网络，用于基因和医学信息的安全共享。Soon-Shiong博士发明并开发了Abraxane，全国首个食品药品监督管理局（FDA）批准的蛋白质纳米颗粒白蛋白结合递送技术，用于治疗癌症。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon-Shiong博士曾担任两家全球制药公司American Pharmaceutical Partners（2008年以46亿美元出售给Fresenius SE）和Abraxis BioScience（2010年以38亿美元出售给新基医药公司）的创始人、董事长和首席执行官。2018年，他成为《洛杉矶时报》、《洛杉矶时报》和《加州时报》旗下其他出版物的所有者和执行董事长。Soon-Shiong博士是Chan Soon-Shiong家族基金会和非营利性医学研究组织Chan Soon-Shiong分子医学研究所的主席。他还担任Access to Advanced Health研究所的董事会主席，该研究所是一家位于西雅图的非营利性生物技术研究机构，专注于与世界上一些最致命的疾病作斗争，包括新冠肺炎、癌症、真菌和寄生虫感染以及其他非传染性疾病。他是伦敦帝国理工学院的客座教授。Soon-Shiong博士拥有威特沃特斯兰德大学的医学学位和不列颠哥伦比亚大学的科学硕士学位。
- Patrick Soon Shiong,is the Founder of ImmunityBio, Inc. He was appointed Executive Chairman of the Board in October 2020 and Global Chief Scientific and Medical Officer of the company on August 11, 2021. Previously, he served as the Chairman of the Board and Chief Executive Officer from March 2015 to October 2020, as the Co-Chairman of the Board from December 2014 to March 2015, and as Immunitybio, Inc. Chief Medical Officer from January 2015 to March 2015. In 2011, he founded NantWorks, LLC (NantWorks), an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon-Shiong invented and developed Abraxane, the nation's first Food and Drug Administration (FDA)-approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010, Dr. Soon-Shiong served as founder, chairman, and chief executive officer of two global pharmaceutical companies, American Pharmaceutical Partners (sold to Fresenius SE for $4.6 billion in 2008) and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). In 2018, he became the owner and executive chairman of the Los Angeles Times, Los Angeles Times en Espaol and other publications under the California Times. Dr. Soon-Shiong is chairman of the Chan Soon-Shiong Family Foundation and the Chan Soon-Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He also serves as chair of the board of directors of the Access to Advanced Health Institute, a nonprofit biotech research institute located in Seattle focused on combating some of the world's deadliest diseases, including COVID-19, cancer, fungal and parasitic infections, and other non-communicable diseases. He is a visiting Professor at the Imperial College of London. Dr. Soon-Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia.
- Bruce Wendel
-
Bruce Wendel于2018年4月至2019年5月期间担任药物开发公司ProMetic Biosciences Ltd.的首席业务发展官。他还曾于2012年7月至2018年7月担任深圳Hepalink制药公司美国子公司Hepalink USA的首席战略官，并于2014年12月至2015年6月担任Scientific Protein Laboratories，LLC的首席执行官。在此之前，在Abraxis BioScience，LLC担任越来越多的职责后，他被任命为副董事长兼首席执行官，负责监督Abraxane的商业化进程，并领导最终于2010年被新基医药公司收购该公司的谈判。1988年，他在百时美施贵宝公司（纽约证券交易所代码：BMY）开始了14年的工作，担任内部法律顾问，之后转向全球业务和企业发展，在那里他担任的角色越来越重要。随后，他在IVAX Corporation担任业务发展副总裁，并于2020年11月至2025年5月在American Pharmaceutical Partners，Inc.担任GT BioPharma，Inc.（纳斯达克：GTBP）的董事会成员，并于2016年6月至2021年5月在Verastem, Inc.（纳斯达克：VSTM）的董事会成员。他还担任过ProMetic Biosciences Ltd.的董事。他获得了乔治敦大学法学院的法学博士学位，以及康奈尔大学的学士学位。
Bruce Wendel served as Chief Business Development Officer for ProMetic Biosciences Ltd., a pharmaceutical development company, from April 2018 to May 2019. He also served as Chief Strategic Officer of Hepalink USA, the U.S. subsidiary of Shenzhen Hepalink Pharmaceutical Company, from July 2012 to July 2018 and as Chief Executive Officer of Scientific Protein Laboratories, LLC from December 2014 to June 2015. Prior to this, having served in roles of increasing responsibility at Abraxis BioScience, LLC, he was appointed Vice Chairman and Chief Executive Officer, overseeing the commercialization of Abraxane and leading the negotiations that culminated in the acquisition of the company by Celgene Corporation in 2010. He began his 14 years at Bristol Myers Squibb Company (NYSE:BMY) in 1988 as in house counsel before shifting to global business and corporate development where he served in roles of increasing responsibility. Subsequently, he was Vice President of Business Development at IVAX Corporation, and at American Pharmaceutical Partners, Inc. From November 2020 to May 2025, he served on the board of directors of GT BioPharma, Inc. (Nasdaq:GTBP), and from June 2016 through May 2021, he served on the board of directors of Verastem, Inc. (Nasdaq:VSTM). He also served as a director of ProMetic Biosciences Ltd. He earned a juris doctor degree from Georgetown University Law School, and a B.S. from Cornell University. - Bruce Wendel于2018年4月至2019年5月期间担任药物开发公司ProMetic Biosciences Ltd.的首席业务发展官。他还曾于2012年7月至2018年7月担任深圳Hepalink制药公司美国子公司Hepalink USA的首席战略官，并于2014年12月至2015年6月担任Scientific Protein Laboratories，LLC的首席执行官。在此之前，在Abraxis BioScience，LLC担任越来越多的职责后，他被任命为副董事长兼首席执行官，负责监督Abraxane的商业化进程，并领导最终于2010年被新基医药公司收购该公司的谈判。1988年，他在百时美施贵宝公司（纽约证券交易所代码：BMY）开始了14年的工作，担任内部法律顾问，之后转向全球业务和企业发展，在那里他担任的角色越来越重要。随后，他在IVAX Corporation担任业务发展副总裁，并于2020年11月至2025年5月在American Pharmaceutical Partners，Inc.担任GT BioPharma，Inc.（纳斯达克：GTBP）的董事会成员，并于2016年6月至2021年5月在Verastem, Inc.（纳斯达克：VSTM）的董事会成员。他还担任过ProMetic Biosciences Ltd.的董事。他获得了乔治敦大学法学院的法学博士学位，以及康奈尔大学的学士学位。
- Bruce Wendel served as Chief Business Development Officer for ProMetic Biosciences Ltd., a pharmaceutical development company, from April 2018 to May 2019. He also served as Chief Strategic Officer of Hepalink USA, the U.S. subsidiary of Shenzhen Hepalink Pharmaceutical Company, from July 2012 to July 2018 and as Chief Executive Officer of Scientific Protein Laboratories, LLC from December 2014 to June 2015. Prior to this, having served in roles of increasing responsibility at Abraxis BioScience, LLC, he was appointed Vice Chairman and Chief Executive Officer, overseeing the commercialization of Abraxane and leading the negotiations that culminated in the acquisition of the company by Celgene Corporation in 2010. He began his 14 years at Bristol Myers Squibb Company (NYSE:BMY) in 1988 as in house counsel before shifting to global business and corporate development where he served in roles of increasing responsibility. Subsequently, he was Vice President of Business Development at IVAX Corporation, and at American Pharmaceutical Partners, Inc. From November 2020 to May 2025, he served on the board of directors of GT BioPharma, Inc. (Nasdaq:GTBP), and from June 2016 through May 2021, he served on the board of directors of Verastem, Inc. (Nasdaq:VSTM). He also served as a director of ProMetic Biosciences Ltd. He earned a juris doctor degree from Georgetown University Law School, and a B.S. from Cornell University.
- Cheryl L. Cohen
-
Cheryl L. Cohen，2011年9月她被任命为首席商务官。从2008年9月到2011年9月，她担任CLC Consulting公司总裁，这是一家专注于新产品启动和商业化的制药和生物科技咨询公司，在那里她负责为确保成功启动提供战略和战术计划。从2001年11月到2008年9月，她担任Health Care Systems 公司战略商业部副总裁，这是Johnson & Johnson 公司在管理市场、合同和供应链方面的子公司，在那里，她直接负责在全国其中一个最大的健康计划和Johnson & Johnson 公司产品的取得事务。从1998年到2007年，她在Centocor 公司工作，是Johnson & Johnson 的一家子公司，她担任多个高级销售职位，包括风湿病专营的副总裁，主要负责美国类风湿性关节炎方面每年10亿美元以上的收入和该公司170人的销售和市场营销团队。她在Solvay制药公司开始她的职业生涯，担任多个销售职位。她在圣若瑟学院（Saint Joseph College）得到学士学位。
Cheryl L. Cohen has been a director of MEI Pharma since April 2020. Ms. Cohen has more than 25 years of leadership experience within the pharmaceutical and biotechnology industries. She currently serves as President of CLC Consulting, a pharmaceutical and biotechnology consulting firm which she incorporated in 2008 that specializes in new product start-ups and commercialization. Most recently, Ms. Cohen served as Chief Commercial Officer of Medivation, Inc. where she built the company's commercial organization and lead her team to successfully launch the blockbuster oncology drug, Xtandi. In 2016 Medivation was acquired by Pfizer Inc. for $14 billion. Prior to joining Medivation, Ms. Cohen spent over 10 years at Johnson & Johnson - most notably as Vice President of the Rheumatology Franchise. In this role, Ms. Cohen was responsible for over $2 billion in annual sales and led multiple commercial entities including marketing, sales, and life cycle management. From June 1998 through November 2007 Ms. Cohen oversaw multiple launches of Remicade in several indications across a variety of specialties including Gastroenterology and Rheumatology. Ms. Cohen began her career at Solvay Pharmaceuticals in management and sales. Ms. Cohen currently serves on the board of directors of Aerpio Pharmaceuticals, Immunity Bio previously NantKwest and Ignyte Acquisition Corp., all of which are publicly traded companies. She earned a B. A. degree from Saint Joseph College. - Cheryl L. Cohen，2011年9月她被任命为首席商务官。从2008年9月到2011年9月，她担任CLC Consulting公司总裁，这是一家专注于新产品启动和商业化的制药和生物科技咨询公司，在那里她负责为确保成功启动提供战略和战术计划。从2001年11月到2008年9月，她担任Health Care Systems 公司战略商业部副总裁，这是Johnson & Johnson 公司在管理市场、合同和供应链方面的子公司，在那里，她直接负责在全国其中一个最大的健康计划和Johnson & Johnson 公司产品的取得事务。从1998年到2007年，她在Centocor 公司工作，是Johnson & Johnson 的一家子公司，她担任多个高级销售职位，包括风湿病专营的副总裁，主要负责美国类风湿性关节炎方面每年10亿美元以上的收入和该公司170人的销售和市场营销团队。她在Solvay制药公司开始她的职业生涯，担任多个销售职位。她在圣若瑟学院（Saint Joseph College）得到学士学位。
- Cheryl L. Cohen has been a director of MEI Pharma since April 2020. Ms. Cohen has more than 25 years of leadership experience within the pharmaceutical and biotechnology industries. She currently serves as President of CLC Consulting, a pharmaceutical and biotechnology consulting firm which she incorporated in 2008 that specializes in new product start-ups and commercialization. Most recently, Ms. Cohen served as Chief Commercial Officer of Medivation, Inc. where she built the company's commercial organization and lead her team to successfully launch the blockbuster oncology drug, Xtandi. In 2016 Medivation was acquired by Pfizer Inc. for $14 billion. Prior to joining Medivation, Ms. Cohen spent over 10 years at Johnson & Johnson - most notably as Vice President of the Rheumatology Franchise. In this role, Ms. Cohen was responsible for over $2 billion in annual sales and led multiple commercial entities including marketing, sales, and life cycle management. From June 1998 through November 2007 Ms. Cohen oversaw multiple launches of Remicade in several indications across a variety of specialties including Gastroenterology and Rheumatology. Ms. Cohen began her career at Solvay Pharmaceuticals in management and sales. Ms. Cohen currently serves on the board of directors of Aerpio Pharmaceuticals, Immunity Bio previously NantKwest and Ignyte Acquisition Corp., all of which are publicly traded companies. She earned a B. A. degree from Saint Joseph College.
高管简历
中英对照 | 中文 | 英文- Richard Adcock
Richard Adcock，自2020年10月起担任首席执行官，自2021年3月起担任公司总裁和董事会成员。他在医疗保健行业拥有超过30年的领导经验。2018年1月至2020年9月，他担任加利福尼亚州Verity Health System，Inc.（Verity Health）的首席执行官，这是一家非营利性公益公司医疗保健提供商，他通过一次成功的重组事件指导了该公司。在加入Verity Health之前，他曾在Sanford Health（一家非营利性综合医疗保健交付系统）担任过各种职务，包括在2004年至2017年期间担任其首席创新官、总裁、执行副总裁和董事。在加入Sanford Health之前，他曾在GE Healthcare担任全球工程总监。Adcock先生拥有北方州立大学工商管理学士学位和凤凰城大学医疗保健管理硕士学位。
Richard Adcock,has served as Chief Executive Officer since October 2020 and as President of the company and a member of the Board since March 2021.He has over 30 years of leadership experience in the healthcare industry. From January 2018 to September 2020, he served as chief executive officer of Verity Health System of California, Inc. (Verity Health), a nonprofit public benefit corporation healthcare provider, that he steered through a successful restructuring event. Prior to joining Verity Health, he served in various capacities at Sanford Health, a not-for-profit integrated healthcare delivery system, including as its chief innovation officer, president, executive vice president and director from 2004 to 2017. Prior to Sanford Health, he served as global engineering director at GE Healthcare. Mr. Adcock holds a B.S. in Business Administration from Northern State University and an M.B.A. in Healthcare Management from University of Phoenix.- Richard Adcock，自2020年10月起担任首席执行官，自2021年3月起担任公司总裁和董事会成员。他在医疗保健行业拥有超过30年的领导经验。2018年1月至2020年9月，他担任加利福尼亚州Verity Health System，Inc.（Verity Health）的首席执行官，这是一家非营利性公益公司医疗保健提供商，他通过一次成功的重组事件指导了该公司。在加入Verity Health之前，他曾在Sanford Health（一家非营利性综合医疗保健交付系统）担任过各种职务，包括在2004年至2017年期间担任其首席创新官、总裁、执行副总裁和董事。在加入Sanford Health之前，他曾在GE Healthcare担任全球工程总监。Adcock先生拥有北方州立大学工商管理学士学位和凤凰城大学医疗保健管理硕士学位。
- Richard Adcock,has served as Chief Executive Officer since October 2020 and as President of the company and a member of the Board since March 2021.He has over 30 years of leadership experience in the healthcare industry. From January 2018 to September 2020, he served as chief executive officer of Verity Health System of California, Inc. (Verity Health), a nonprofit public benefit corporation healthcare provider, that he steered through a successful restructuring event. Prior to joining Verity Health, he served in various capacities at Sanford Health, a not-for-profit integrated healthcare delivery system, including as its chief innovation officer, president, executive vice president and director from 2004 to 2017. Prior to Sanford Health, he served as global engineering director at GE Healthcare. Mr. Adcock holds a B.S. in Business Administration from Northern State University and an M.B.A. in Healthcare Management from University of Phoenix.
- David Sachs
David Sachs，自2021年3月起担任首席财务官。此前，他曾于2019年7月至2021年3月担任NantCell，Inc.的首席财务官。他还曾于2018年2月至2020年8月担任Integrity Healthcare，LLC（NantWorks子公司）的首席财务官。2011年4月至2019年6月，他在NantWorks及其子公司担任多个行政职务，包括2013年至2015年担任NantHealth公司首席财务官。在加入NantWorks之前，他曾在新基医药公司和Abraxis BioScience担任业务发展职务，并在美银美林担任投资银行家。萨克斯先生在加州大学洛杉矶分校获得经济学学士学位，在加州大学洛杉矶分校安德森管理学院获得金融和战略硕士学位。
David Sachs,has served as Chief Financial Officer since March 2021. He previously served as the chief financial officer of NantCell, Inc. from July 2019 to March 2021. He also served as chief financial officer of Integrity Healthcare, LLC (a NantWorks subsidiary) from February 2018 to August 2020. From April 2011 to June 2019, he held various executive positions at NantWorks and its subsidiaries, including serving as chief financial officer of NantHealth, Inc. from 2013 to 2015. Prior to NantWorks, he served in business development roles at Celgene Corporation and Abraxis BioScience and as an investment banker with Bank of America Merrill Lynch. Mr. Sachs received his B.A. in Economics from the University of California at Los Angeles and his M.B.A. in Finance and Strategy from the UCLA Anderson School of Management.- David Sachs，自2021年3月起担任首席财务官。此前，他曾于2019年7月至2021年3月担任NantCell，Inc.的首席财务官。他还曾于2018年2月至2020年8月担任Integrity Healthcare，LLC（NantWorks子公司）的首席财务官。2011年4月至2019年6月，他在NantWorks及其子公司担任多个行政职务，包括2013年至2015年担任NantHealth公司首席财务官。在加入NantWorks之前，他曾在新基医药公司和Abraxis BioScience担任业务发展职务，并在美银美林担任投资银行家。萨克斯先生在加州大学洛杉矶分校获得经济学学士学位，在加州大学洛杉矶分校安德森管理学院获得金融和战略硕士学位。
- David Sachs,has served as Chief Financial Officer since March 2021. He previously served as the chief financial officer of NantCell, Inc. from July 2019 to March 2021. He also served as chief financial officer of Integrity Healthcare, LLC (a NantWorks subsidiary) from February 2018 to August 2020. From April 2011 to June 2019, he held various executive positions at NantWorks and its subsidiaries, including serving as chief financial officer of NantHealth, Inc. from 2013 to 2015. Prior to NantWorks, he served in business development roles at Celgene Corporation and Abraxis BioScience and as an investment banker with Bank of America Merrill Lynch. Mr. Sachs received his B.A. in Economics from the University of California at Los Angeles and his M.B.A. in Finance and Strategy from the UCLA Anderson School of Management.
- Patrick Soon Shiong
Patrick Soon Shiong，是ImmunityBio公司的创始人，他于2020年10月被任命为董事会执行主席，并于2021年8月11日被任命为公司全球首席科学和医疗官。此前，他于2015年3月至2020年10月担任董事会主席兼首席执行官，于2014年12月至2015年3月担任董事会联席主席，并于2015年1月至2015年3月担任ImmunityBio, Inc.首席医疗官。2011年，他创立了NantWorks，LLC（NantWorks），这是一个由公司组成的生态系统，旨在创建一个变革性的全球健康信息和下一代药物开发网络，用于基因和医学信息的安全共享。Soon-Shiong博士发明并开发了Abraxane，全国首个食品药品监督管理局（FDA）批准的蛋白质纳米颗粒白蛋白结合递送技术，用于治疗癌症。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon-Shiong博士曾担任两家全球制药公司American Pharmaceutical Partners（2008年以46亿美元出售给Fresenius SE）和Abraxis BioScience（2010年以38亿美元出售给新基医药公司）的创始人、董事长和首席执行官。2018年，他成为《洛杉矶时报》、《洛杉矶时报》和《加州时报》旗下其他出版物的所有者和执行董事长。Soon-Shiong博士是Chan Soon-Shiong家族基金会和非营利性医学研究组织Chan Soon-Shiong分子医学研究所的主席。他还担任Access to Advanced Health研究所的董事会主席，该研究所是一家位于西雅图的非营利性生物技术研究机构，专注于与世界上一些最致命的疾病作斗争，包括新冠肺炎、癌症、真菌和寄生虫感染以及其他非传染性疾病。他是伦敦帝国理工学院的客座教授。Soon-Shiong博士拥有威特沃特斯兰德大学的医学学位和不列颠哥伦比亚大学的科学硕士学位。
Patrick Soon Shiong,is the Founder of ImmunityBio, Inc. He was appointed Executive Chairman of the Board in October 2020 and Global Chief Scientific and Medical Officer of the company on August 11, 2021. Previously, he served as the Chairman of the Board and Chief Executive Officer from March 2015 to October 2020, as the Co-Chairman of the Board from December 2014 to March 2015, and as Immunitybio, Inc. Chief Medical Officer from January 2015 to March 2015. In 2011, he founded NantWorks, LLC (NantWorks), an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon-Shiong invented and developed Abraxane, the nation's first Food and Drug Administration (FDA)-approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010, Dr. Soon-Shiong served as founder, chairman, and chief executive officer of two global pharmaceutical companies, American Pharmaceutical Partners (sold to Fresenius SE for $4.6 billion in 2008) and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). In 2018, he became the owner and executive chairman of the Los Angeles Times, Los Angeles Times en Espaol and other publications under the California Times. Dr. Soon-Shiong is chairman of the Chan Soon-Shiong Family Foundation and the Chan Soon-Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He also serves as chair of the board of directors of the Access to Advanced Health Institute, a nonprofit biotech research institute located in Seattle focused on combating some of the world's deadliest diseases, including COVID-19, cancer, fungal and parasitic infections, and other non-communicable diseases. He is a visiting Professor at the Imperial College of London. Dr. Soon-Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia.- Patrick Soon Shiong，是ImmunityBio公司的创始人，他于2020年10月被任命为董事会执行主席，并于2021年8月11日被任命为公司全球首席科学和医疗官。此前，他于2015年3月至2020年10月担任董事会主席兼首席执行官，于2014年12月至2015年3月担任董事会联席主席，并于2015年1月至2015年3月担任ImmunityBio, Inc.首席医疗官。2011年，他创立了NantWorks，LLC（NantWorks），这是一个由公司组成的生态系统，旨在创建一个变革性的全球健康信息和下一代药物开发网络，用于基因和医学信息的安全共享。Soon-Shiong博士发明并开发了Abraxane，全国首个食品药品监督管理局（FDA）批准的蛋白质纳米颗粒白蛋白结合递送技术，用于治疗癌症。Abraxane于2005年被FDA批准用于转移性乳腺癌，2012年被批准用于肺癌，2013年被批准用于胰腺癌。Abraxane现已在全球多个国家获得批准。从1997年到2010年，Soon-Shiong博士曾担任两家全球制药公司American Pharmaceutical Partners（2008年以46亿美元出售给Fresenius SE）和Abraxis BioScience（2010年以38亿美元出售给新基医药公司）的创始人、董事长和首席执行官。2018年，他成为《洛杉矶时报》、《洛杉矶时报》和《加州时报》旗下其他出版物的所有者和执行董事长。Soon-Shiong博士是Chan Soon-Shiong家族基金会和非营利性医学研究组织Chan Soon-Shiong分子医学研究所的主席。他还担任Access to Advanced Health研究所的董事会主席，该研究所是一家位于西雅图的非营利性生物技术研究机构，专注于与世界上一些最致命的疾病作斗争，包括新冠肺炎、癌症、真菌和寄生虫感染以及其他非传染性疾病。他是伦敦帝国理工学院的客座教授。Soon-Shiong博士拥有威特沃特斯兰德大学的医学学位和不列颠哥伦比亚大学的科学硕士学位。
- Patrick Soon Shiong,is the Founder of ImmunityBio, Inc. He was appointed Executive Chairman of the Board in October 2020 and Global Chief Scientific and Medical Officer of the company on August 11, 2021. Previously, he served as the Chairman of the Board and Chief Executive Officer from March 2015 to October 2020, as the Co-Chairman of the Board from December 2014 to March 2015, and as Immunitybio, Inc. Chief Medical Officer from January 2015 to March 2015. In 2011, he founded NantWorks, LLC (NantWorks), an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information. Dr. Soon-Shiong invented and developed Abraxane, the nation's first Food and Drug Administration (FDA)-approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe. From 1997 to 2010, Dr. Soon-Shiong served as founder, chairman, and chief executive officer of two global pharmaceutical companies, American Pharmaceutical Partners (sold to Fresenius SE for $4.6 billion in 2008) and Abraxis BioScience (sold to Celgene Corporation for $3.8 billion in 2010). In 2018, he became the owner and executive chairman of the Los Angeles Times, Los Angeles Times en Espaol and other publications under the California Times. Dr. Soon-Shiong is chairman of the Chan Soon-Shiong Family Foundation and the Chan Soon-Shiong Institute of Molecular Medicine, a nonprofit medical research organization. He also serves as chair of the board of directors of the Access to Advanced Health Institute, a nonprofit biotech research institute located in Seattle focused on combating some of the world's deadliest diseases, including COVID-19, cancer, fungal and parasitic infections, and other non-communicable diseases. He is a visiting Professor at the Imperial College of London. Dr. Soon-Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia.